Aktis Oncology, Inc. (AKTS)
Free
No email, no account, no signup.
Pulling latest news for Aktis Oncology, Inc.…
Bull
Bear
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Order analysis – $4.99
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
NASDAQ
Type
Biotech
Sector
Targeted radiopharmaceuticals
Market Cap
$1.1B
We're already tracking Aktis Oncology, Inc. — here are the latest events we've registered
Recent News
- In May 2026, Aktis Oncology initiated a Phase 1b clinical trial for AKY-2519 in patients with metastatic castration-resistant prostate cancer. This follows the company's $365 million initial public offering on the Nasdaq in January 2026 and the FDA granting Fast Track designation to its lead candidate, AKY-1189, in February. Preliminary data from its ongoing clinical trials are expected in 2027.
Want to know how this news affects Aktis Oncology, Inc.? Order the analysis.
Order analysis – $4.99
What you get
A complete express analysis — not just a signal. Delivered as a webpage in your account.
- Signal: BUY / HOLD / SELL — with clear reasoning
- Sentiment score 1–10 based on news, reports, and market data
- Risk score 1–10 (dilution, jurisdiction, execution)
- Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
- Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
- Upcoming catalysts with dates
- Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Aktis Oncology, Inc. will be delivered in the same format.
Not satisfied? Get your money back within 7 days — no questions asked.
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.